ClinicalTrials.gg
RecruitingNCT06860269GRAALL-2024Updated Feb 10, 2026

A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

A Phase 2/3 interventional study of Randomization + Blinatumomab + chemotherapy and Randomization + Standard frontline T-ALL chemotherapy backbone in Acute Lymphoblastic Leukemia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris — 8 open to participants now, 10 under way, 3 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
2nd of 12
1,200 · median 161
Started
2025
the only one that year
Phase 2/3
2 of 18
1 open now
Registered
17th of 18
by date

Among the 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 17th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

8 of the 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Adult acute lymphoblastic leukemia (ALL) includes Ph-positive (Phpos) ALL, Ph-negative (Phneg) B-cell precursor (BCP) ALL and T-ALL/lymphoblastic lymphoma (LL), accounting for approximately 25, 50 and 25% of all cases, respectively. In younger adults, the results associated with standard therapy have markedly improved in these 3 groups, due to chemotherapy intensification in the BCP and T groups and addition of TKIs in the Phpos group, respectively. This led to reevaluate the role of allogeneic hematopoietic stem cell transplantation (HSCT) in first remission, which is generally now indicated only in higher-risk patients, mostly defined as those with persistent high levels of minimal residual disease (MRD). Nevertheless, event-free survival (EFS) remains at 60-70% at 3 years, meaning there is still room for further improvements.

Fortunately, new immunotherapies have been approved to treat relapsed/refractory (R/R) BCP-ALL patients, including the anti-CD19 bispecific T-cell engager blinatumomab (BLINA, Blincyto®, Amgen). 4 BLINA is also approved for the frontline treatment of patients with persistent high measurable residual disease (MRD) levels after initial therapy (IG/TR MRD ≥0.1% (≥1.10-3

)). BLINA has been also evaluated frontline in combination with TKI in the Phpos group leading to promising outcome improvements. Toxicities associated with these combined treatments seem to be limited and manageable. In the Phpos ALL subset, the third-generation tyrosine kinase inhibitor ponatinib (PONA, Iclusig®, Incyte) has also been evaluated frontline with promising results when compared to 1st or even 2nd generation TKI. In the T-ALL/LL subset, anti-CD38 antibodies, approved to treat patients with multiple myeloma, are potential drugs of interest. The anti-CD38 antibody isatuximab (ISA, Sarclisa®, Immunogen, Sanofi-Aventis) is currently approved to treat myeloma patients in 2nd line. In vitro and in vivo preclinical studies suggest that CD38 is a relevant target in T-ALL and that isatuximab may be useful to eradicate residual disease in this subgroup of patients. Incorporation/combination of these new agents into frontline adult ALL therapy could allow reducing relapse incidence and prolonging survival in these patients, challenging the indication for HSCT in first complete remission (CR).

The present GRAALL-2024 study is a prospective multicenter multi-country 3-cohort randomized clinical trial.

The 3 cohorts are :

GRAALL-2024/B : Phneg BCP-ALL GRAAPH-2024 : Phpos ALL GRAALL-2024/T : T-ALL/LL

Eligible patients will be allocated to one on the 3 study cohorts during a common treatment prephase. The primary objective of the study is to improve the outcome of younger adults with ALL through optimal frontline incorporation of new antibody-based therapies, including BLINA in Phneg/pos BCP-ALL patients and ISA in T-ALL/LL patients, and to refine indication for allogeneic HSCT in first remission in Phneg/pos BCP-ALL patients.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 to 65 years old
  2. Newly diagnosed ALL or T-LL according to the WHO criteria
  3. Immunophenotypic, cytogenetic and/or FISH and molecular evaluation performed and allowing classifying the patient in one of the Phpos ALL, Phneg BCP-ALL or T-ALL/LL cohorts
  4. Not previously treated except with and/or intrathecal therapy (prephase)
  5. Eligible for if Phpos ALL or Phneg BCP-ALL
  6. performance status ≤2
  7. Patient willing and able to understand the protocol requirements and comply with the treatment schedule, scheduled visits, electronic patient outcome reporting, exams and other requirements of the study
  8. Patients has signed written inform consent
  9. Willingness of women of (WOCBP) and male subjects whose sexual partners are WOCBP to use an effective form of , i.e. methods with a failure rate of \<1% per year when used consistently and correctly, during the study and at least 6 months thereafter
  10. Eligible for National Health Insurance (for French patients)

Exclusion criteria

Exclusion Criteria:

Common exclusion criteria :

  1. Patient previously treated with systemic chemotherapy, antibody-based therapy or TKI
  2. Patients with a history of another primary that is currently or currently requires active intervention
  3. History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, coordination/movement disorder, disease with CNS involvement, psychosis (with the exception of CNS leukemia that is well controlled with intrathecal therapy)
  4. Patients with \<50% or other clinically significant heart disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension)
  5. Prior documented chronic liver disease. Inadequate hepatic functions defined as or ALT > 5 x the institutional (ULN), or > 5 x ULN unless if considered due to leukemia. Total > 1.5 x ULN unless if considered due to leukemia or Gilbert/Meulengracht
  6. Estimated (GFR) \< 50 mL/mn using the MDRD equation
  7. Chronic pancreatitis or acute pancreatitis within 6 months before study start
  8. Known diagnosis of (HIV) infection (HIV testing is not mandatory) or active infection with or C.
  9. Concurrent severe diseases which exclude the administration of therapy
  10. Treatment with any other agent or participating in another trial within 30 days prior to entering this study
  11. Pregnancy and breast feeding
  12. Patients unwilling or unable to comply with the protocol
  13. Patients under a legal protection regime (guardianship, trusteeship, judicial safeguard)
  14. Chronic or current active uncontrolled infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
  15. Current use of prohibited medication
  16. Known or severe reaction to ponatinib (GRAAPH), blinatumomab (GRAAPH and GRAALL-B) , isatuximab (GRAALL-T) or their .
  17. Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study

If patients with Phpos ALL:

  1. Complete left bundle branch block, right bundle branch block plus left anterior hemiblock, bi-fascicular block
  2. History of or presence of clinically significant ventricular or atrial tachyarrhythmias
  3. Clinically significant resting bradycardia (\< 50 beats per minute)
  4. Congenital long syndrome or QTcF > 470 msec on screening . If QTc > 470 msec and electrolytes are not within normal ranges before ponatinib dosing, electrolytes should be corrected and then the patient rescreened for QTcF criterion
  5. Currently taking drug(s) that are known to have a risk of causing prolonged QTc or TdP unless the drug(s) can be changed to acceptable alternatives (ie, an alternate class of agents that do not affect the cardiac conduction system), or the participant can safely discontinue the drug(s)
  6. Previous myocardial infarction within the last 12 months
  7. Symptomatic peripheral vascular disease
  8. History of ischemic stroke or (TIAs) within the last 12 months
  9. Significant bleeding disorder or thrombophilia unrelated to the underlying malignancy indication for study participation
  10. Gastrointestinal disorders, such as malabsorption syndrome or any other illness that could affect oral absorption
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • No intervention
    GRAALL-2024/B Very High Risk - SOC

    Phneg BCP-ALL cohort Standard of Care : ALLO HSCT

  • Active comparator
    GRAALL-2024/B High Risk - SOC

    Phneg BCP-ALL cohort

    Other: Randomization 1 + Allo HSCT

  • Experimental
    GRAALL-2024/B High risk - Blina

    Phneg BCP-ALL cohort

    Drug: Randomization + Blinatumomab + chemotherapy

  • No intervention
    GRAALL-2024/B Standard Risk - SOC

    Phneg BCP-ALL cohort Standard of Care : Blinatumomab + chemotherapy

  • Active comparator
    GRAALL-2024/T - SOC

    T-ALL cohort

    Other: Randomization + Standard frontline T-ALL chemotherapy backbone

  • Experimental
    GRAALL-2024/T - Isa

    T-ALL cohort

    Drug: Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone

  • No intervention
    GRAAL-2024/T - T-cell lymphoblastic lymphoma - SOC

    Non randomized - standard care

  • Active comparator
    GRAAPH-2024 - SOC

    Phpos ALL cohort

    Other: Randomization 2 + Allo HSCT

  • Experimental
    GRAAPH-2024 - Blina/Pona

    Phpos ALL cohort

    Drug: Randomization + Blinatumomab + Ponatinib + chemotherapy

Interventions

  • DrugRandomization + Blinatumomab + chemotherapy

    Rando 1 : BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 4 cycles (first cycle starts with 9 µg/day for 7 days)

  • OtherRandomization + Standard frontline T-ALL chemotherapy backbone

    Rando 3 : standard of care

  • DrugRandomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone

    Rando 3 : ISA will be given at 10 mg/kg IV for a maximum of 28 infusions starting at induction up to maintenance phase.

  • DrugRandomization + Blinatumomab + Ponatinib + chemotherapy

    Rando 2 : * PONA will be given at 45 mg/day PO during 2 cycles, 30 mg/day during 2 additional cycles, and 15 mg/day during maintenance phase or after alloHSCT * BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 5 cycles (first cycle starts with 9 µg/day for 7 days). Patients allografted will receive two courses before transplant.

  • OtherRandomization 1 + Allo HSCT

    Rando 1 : standard of care - Allogeneic Hematopoietic Stem Cell Transplantation

  • OtherRandomization 2 + Allo HSCT

    Rando 2 : standard of care

06

What researchers measure

Primary outcomes

  1. Overall survival

    For GRAAL-2024/B HR patients (phase 3)

    Time frame: At 5 years

  2. Overall survival

    For GRAAL-2024/B SR patients (phase 2)

    Time frame: At 5 years

  3. Event-Free Survival

    For GRAAL-2024/T patients (phase 3)

    Time frame: At 5 years

  4. Overall survival

    For GRAAPH-2024 patients (phase 3) - Phpos ALL

    Time frame: At 5 years

Secondary outcomes

  1. Overall survival

    in the T-ALL/LL cohorts

    Time frame: At 5 years

  2. Event Free Survival

    Time frame: At 5 years

  3. Relapse Free Survival

    Time frame: At 5 years

  4. Hematological complete response rate

    After induction

    Time frame: At 45 days

  5. Hematological complete response rate

    After consolidation

    Time frame: At 4 months

  6. Measurable residual disease (MRD) response level

    (IG/TR and BCR::ABL1 markers) at diagnosis

    Time frame: At inclusion

  7. Measurable residual disease (MRD) response level - non graft patients

    (IG/TR and BCR::ABL1 markers) After each treatment cycle until maintenance (4 to 5 times)

    Time frame: Up to 6 months

  8. Measurable residual disease (MRD) response level - graft patients

    (IG/TR and BCR::ABL1 markers) At day 100 post-HSCT and every 3 months post HSCT for patients receiving allo-HSCT during maintenance up to 2 years

    Time frame: Through study completion, approximately 5 years

  9. Measurable residual disease (MRD) response level

    (IG/TR and BCR::ABL1 markers) At relapse

    Time frame: Up to 5 years

  10. Early mortality

    Time frame: At day 30

  11. Early mortality

    Time frame: At day 60

  12. Early mortality

    Time frame: At day 90

  13. Cumulative incidence of relapse (CIR)

    Time frame: At 5 years

  14. Cumulative incidence of non relapse mortality

    Time frame: At 5 years

  15. Transplant-related mortality (TRM)

    For graft patients

    Time frame: At 5 years

  16. Graft-versus-host-disease (GvHD) incidence

    For graft patients

    Time frame: At 5 years

  17. Number of patients who experience one or more Adverse Event (AEs) or Serious Adverse Event (SAEs)

    Time frame: At 5 years

  18. Rate of patients who experience one or more Adverse Event (AEs) or Serious Adverse Event (SAEs)

    Time frame: At 5 years

  19. Quality of life level

    Assessed with EQ5D 5L It evaluates five dimensions : mobility, self-care, usual activities, pain/discomfort and anxiety/depression and each dimension has five levels : no problems, slight problems, moderate problems, severe problems and extreme problems. Answers are given on a 5-point scale by domain, the higher the score, the poorer the quality of life. At each study visit

    Time frame: Until 5 years

  20. Incremental cost effectiveness and cost utility ratio

    Defined as the difference in total costs divided by the difference in survival and in quality adjusted life years

    Time frame: At 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Mar 2035, 118 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Mar 6, 2025
StartActual
May 6, 2025
Primary completionEst.
Mar 15, 2035
CompletionEst.
Mar 15, 2035
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06860269
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
May 6, 2025
Primary completion
Mar 15, 2035 (estimated)
Completion
Mar 15, 2035 (estimated)
Last update
Feb 10, 2026

Study contacts

Nicolas Boissel, MD PhD
Contact
nicolas.boissel@aphp.fr
1 42 49 96 43 ext. +33
Jérôme Lambert, MD PhD
Contact
jerome.lambert@u-paris.fr
0142499742 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion